Plain-English translation of NCT06307652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called balcinrenone, when combined with an existing heart failure drug called dapagliflozin, works better than dapagliflozin alone. The trial will enroll 4,800 people with heart failure and impaired kidney function to see if this combination can reduce life-threatening heart problems and hospitalizations. You would be randomly assigned to receive either the new combination treatment, a higher dose of the combination, or the standard treatment.
People with both heart failure and kidney disease often have worse outcomes and limited treatment options. This medication is being tested to see if it can provide better protection for both the heart and kidneys in this high-risk group.
You likely qualify if…
You likely don't qualify if…
You would take one capsule and one tablet by mouth once daily for approximately 20 months, with regular visits to the clinic for blood tests, heart function checks, and symptom monitoring. Some participants will receive the new combination treatment at one of two doses, while others will receive the standard medication, but neither you nor your doctor will know which group you're in during the study. After the main treatment period ends, there is a one-month follow-up phase, and the total time commitment is estimated at about 22 months.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States